Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Wien Klin Wochenschr ; 135(15-16): 414-419, 2023 Aug.
Article in English | MEDLINE | ID: mdl-36583748

ABSTRACT

OBJECTIVE: Previous studies have shown that Helicobacter pylori (HP) infection is associated with increased activity and severity of systemic sclerosis (SSc), hence we aimed to evaluate the effect of HP eradication on various symptoms and inflammatory indices. METHODS: The SSc patients without dyspeptic symptoms were prospectively enrolled in this 18-month cross-sectional study. Patients were divided into two groups based on determination of HP infection. The infected group was treated in accordance with the current HP eradication protocol. Assessment of disease activity, severity and organ involvement was performed every 6 months. RESULTS: A total of 42 consecutive SSc patients without dyspepsia and variable disease activity and severity were recruited. Levels of modified Rodnan skin score, erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) significantly decreased following HP eradication (p < 0.001, p < 0.001 and p = 0.001, respectively), and in the HP-negative patient group ESR and CRP values increased (p = 0.03, p = 0.002). Eradication of HP in the group of infected patients induced progressive and significant improvement of disease activity and severity over time compared to baseline (p < 0.01, p < 0.001, respectively), whereas in the HP-negative patient group these scores remained unchanged. In our study, HP eradication was associated with an improvement of clinical symptoms and disease activity. CONCLUSION: These findings suggest that HP detection and subsequent eradication could be beneficial in the management of SSc patients. Although, HP eradication seems to be advantageous in infected SSc patients, larger controlled studies are needed for a potential recommendation.


Subject(s)
Dyspepsia , Helicobacter Infections , Helicobacter pylori , Scleroderma, Systemic , Humans , Helicobacter pylori/metabolism , Cross-Sectional Studies , Helicobacter Infections/diagnosis , Helicobacter Infections/drug therapy , Dyspepsia/complications , Dyspepsia/drug therapy , C-Reactive Protein/analysis , Scleroderma, Systemic/complications , Scleroderma, Systemic/diagnosis , Scleroderma, Systemic/drug therapy , Anti-Bacterial Agents/therapeutic use
3.
Rheumatol Int ; 33(11): 2943-8, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23224499

ABSTRACT

Helicobacter pylori (H. pylori) is suspected to be one of the factors triggering systemic sclerosis (SSc). Data on the possible role of H. pylori are lacking. The aim of this study was to assess the effect of H. pylori infection in SSc patients. Forty-two SSc patients without dyspeptic symptoms were recruited--26 were H. pylori-positive and 16 were H. pylori-negative on the basis of invasive test. We evaluated the disease severity using clinical and laboratory parameters according to the Medsger Severity Scale. The level of SSc activity was evaluated according to Valentini activity score. The prevalence of H. pylori infection in population of SSc patients is 62%. Severity of skin, gastrointestinal, and joint/tendon involvement was different between H. pylori-positive and -negative SSc patients (p < 0.001 for skin involvement, p = 0.002 and p = 0.03 for gastrointestinal and joint/tendon involvement, respectively) as well as erythrocyte sedimentation rate (p = 0.002). Severity score according to Medsger was higher in the H. pylori-positive than in the H. pylori-negative SSc patients (p < 0.001). Our data suggest that H. pylori infection correlates with severity of skin, gastrointestinal, and joint/tendon involvement in SSc patients. H. pylori-positive SSc patients showed higher severity score compared to H. pylori-negative. Therefore, H. pylori infection may play a role in the pathogenesis of SSc and also can provide some prognostic information.


Subject(s)
Helicobacter Infections/complications , Helicobacter pylori/isolation & purification , Scleroderma, Systemic/complications , Adult , Aged , Female , Humans , Male , Middle Aged , Prognosis , Risk Factors , Scleroderma, Systemic/diagnosis , Severity of Illness Index
4.
Lijec Vjesn ; 134(7-8): 215-7, 2012.
Article in Croatian | MEDLINE | ID: mdl-23133914

ABSTRACT

Eosinophilic pleural effusion (EPE) is defined as exudative effusion that contains at least 10% eosinophils. The most common conditions associated with EPE are malignancy, infections, post-traumatic and post-surgical conditions, hypersensitivity, systemic autoimmune diseases, congestive heart failure, cirrhosis, pulmonary embolus, asbestosis and drug induced EPE. Pleural effusion accompanying autoimmune diseases is most common in patients with systemic lupus erythematosus, rheumatoid arthritis, howewer it rarely occurs in patients with progressive systemic sclerosis and polymiositis. EPE has rarely been reported in association with Churg Strauss syndrome. In about 14-25% of patients EPE can be defined as idiopathic when diagnostic procedures failed to identify the etiology. Treatment of EPE is based on the treatment of primary disease and with idiopathic form a good answer is reached using glucocorticoids. In this case report we presented the patient with idiopathic eosinophilic pleural effusion where in diagnostic procedures we excluded other diseases or conditions in which EPE can be shown, and with applied therapy with methylprednisolone we achieved excellent clinical response and final healing.


Subject(s)
Eosinophilia , Pleural Effusion , Adult , Eosinophilia/diagnosis , Eosinophilia/etiology , Eosinophilia/therapy , Humans , Male , Pleural Effusion/diagnosis , Pleural Effusion/etiology , Pleural Effusion/therapy
6.
Reumatizam ; 56(1): 30-5, 2009.
Article in Croatian | MEDLINE | ID: mdl-20954306

ABSTRACT

In rheumatoid arthritis (RA) kidney is commonly affected organ with clinical presentation characterised by proteinuria (often nephrotic range) and microhematuria followed by chronic renal failure. This condition is well recognized as a rheumatoid nephropathy (rheumatoid glomerulonephritis), which is mediated by an immunological inflammation and by nephrotoxic effects of numerous drugs usually used in rheumatoid arthiritis treatment, such as NSAID, DMARD. In the patohistological examination various kinds of associated renal lesions could be seen. The most often are amyloidosis, glomerulonephritis, interstitial nephritis. In this study, we presented 15 patients, 10 women and 5 men, mean age of 60.2 with average rheumatoid arthritis duration of 19.4 years and signs of rheumatoid nephropathy. In all patients renal biopsy was performed with frequency of histopathological findings as follows: amyloidosis in 5 patients, IgA nephropathy in 3 patients, FSGS in 3 patients, mesangial proliferative glomerulonephritis in 3 patients, minimal change disease, pauci-immune glomerulonephritis and thin membrane disease in 1 patient. In all patients (except patient with thin membrane nephropathy) we started immunossuppresive therapy with glucocorticoids in combination with cyclophosphamide or cyclosporin or azatioprine. In conclusion, in all patients with rheumatoid arthritis, parameters of renal function should be monitored and in the case of patologic results, renal biopsy should be be performed. In the treatment of RA patients with related renal disorder, suspected causal drug should be removed from the treatment and specific immunosuppressive therapy initiated.


Subject(s)
Arthritis, Rheumatoid/complications , Kidney Diseases/complications , Adult , Antirheumatic Agents/adverse effects , Arthritis, Rheumatoid/drug therapy , Female , Humans , Kidney Diseases/diagnosis , Male , Middle Aged , Young Adult
7.
Reumatizam ; 56(2): 26-8, 2009.
Article in Croatian | MEDLINE | ID: mdl-20429258

ABSTRACT

The complement system has important protective functions in both, the innate and the adoptive immune systems. Dysregulation of complement system can cause the tissue damage. The complement deficiency predispose to an infection, and also to a development of auto-immune diseases, especially systemic lupus erythematosus (SLE). The complement play an important role in the pathogenesis of SLE, and besides that the lower levels of complement's compounds are well recognised as marker of SLE activity and also the activity of secondary APS.


Subject(s)
Complement System Proteins/immunology , Lupus Erythematosus, Systemic/immunology , Antiphospholipid Syndrome/immunology , Complement System Proteins/physiology , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...